Nuclidium

Alpha-9 Theranostics

This clinical-stage biotechnology company develops targeted radiopharmaceuticals to treat cancer patients by delivering radiation directly to tumours while sparing healthy tissue.

Ariceum Therapeutics

This clinical-stage biotechnology company develops targeted radiopharmaceutical therapies for the diagnosis and treatment of aggressive, hard-to-treat cancers.

Cereius

This company develops targeted radiopharmaceuticals and radiodiagnostics for cancer patients, focusing on the treatment of solid tumour brain metastases.

Full-Life Technologies

This company develops radiopharmaceuticals and radionuclide drug conjugates to treat cancer patients through targeted alpha therapy.

RYZB

This company develops targeted radiopharmaceutical therapeutics for patients with solid tumours.

Alpha-9

Alpha-9 Oncology develops targeted radiopharmaceuticals and imaging compounds for the treatment of patients with various types of cancer.

Actithera Group

This company develops radioligand therapies to treat cancer patients by delivering radiation directly to solid tumours while sparing healthy tissue.

Actithera

This biotechnology company develops targeted radioligand therapies to treat cancer patients by delivering radioactive isotopes directly to solid tumours.